Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by kuatoliveson Nov 14, 2018 9:07pm

178 Views

Post# 28977064

RE:RE:2018 revenues to date... well well !!!

Newcamo wrote:
surprising they were able to pull that:) i think the market can only reward 24 million$ increase in sales! Very positive, partnership is being negociated and will be out soon, i say we move up or hold between .40-.50 easy!

Revenues from the sale of goods, representing most of the 2018 revenues to date,were $35.3 million during the first nine months ended September 30, 2018 compared to $11 million during the corresponding 2017 period.The $24.3 million increase for 2018 is mainly due to $19.7 million in sales of normal source plasma which occurred in the second and third quarters of 2018 following a change in the production forecast due to the delay of the BLA approval for RyplazimTM (plasminogen)